177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life

[1] Dasari A(2017)Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States JAMA Oncology. 3 1335-1342

[2] Shen C(2008)One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 3063-3072

[3] Halperin D(2020)Elderly patients with metastatic neuroendocrine tumors are undertreated and have shorter survival: the LyREMeNET study Neuroendocrinology. 110 653-661

[4] Zhao B(2010)Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE) Annals of oncology : official journal of the European Society for Medical Oncology. 21 1794-1803

[5] Zhou S(2014)Personalizing medicine in geriatric oncology J Clin Oncol 32 2581-2586

[6] Xu Y(2003)Participation of patients 65 years of age or older in cancer clinical trials J Clin Oncol 21 1383-1389

[7] Yao JC(2015)Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement J Clin Oncol 33 3826-3833

[8] Hassan M(2016)Inclusion of elderly patients in oncology clinical trials Annals of oncology : official journal of the European Society for Medical Oncology 27 1799-1804

[9] Phan A(2017)Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors Clinical cancer research : an official journal of the American Association for Cancer Research 23 4617-4624

[10] Dagohoy C(2008)Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2124-2130

[1] Dasari A(2017)Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States JAMA Oncology. 3 1335-1342

[2] Shen C(2008)One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 3063-3072

[3] Halperin D(2020)Elderly patients with metastatic neuroendocrine tumors are undertreated and have shorter survival: the LyREMeNET study Neuroendocrinology. 110 653-661

[4] Zhao B(2010)Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE) Annals of oncology : official journal of the European Society for Medical Oncology. 21 1794-1803

[5] Zhou S(2014)Personalizing medicine in geriatric oncology J Clin Oncol 32 2581-2586

[6] Xu Y(2003)Participation of patients 65 years of age or older in cancer clinical trials J Clin Oncol 21 1383-1389

[7] Yao JC(2015)Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement J Clin Oncol 33 3826-3833

[8] Hassan M(2016)Inclusion of elderly patients in oncology clinical trials Annals of oncology : official journal of the European Society for Medical Oncology 27 1799-1804

[9] Phan A(2017)Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors Clinical cancer research : an official journal of the American Association for Cancer Research 23 4617-4624

[10] Dagohoy C(2008)Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2124-2130